Pyxis Oncology Completes Q1 Enrollment, Targets Mid-Year 5.4 mg/kg MICVO Data
PYXS•Pyxis Oncology completed target enrollment for its MICVO Phase 1 monotherapy expansion in 2L+ R/M HNSCC Q1 2026 and expects mid-year data focusing on patients treated at or below a 5.4 mg/kg dose cap. The company projects cash runway into Q4 2026 and plans combination trial updates in H2 2026.
1. Q1 Financial Results and Cash Runway
In the first quarter of 2026, Pyxis Oncology completed target enrollment in its MICVO Phase 1 monotherapy dose expansion for 2L+ R/M HNSCC and confirmed funding to support operations into the fourth quarter of 2026.
2. MICVO Monotherapy Enrollment and Dose Capping
Enrollment in the monotherapy expansion hit its goal in Q1, and the mid-year update will analyze outcomes in patients dosed at or below a 5.4 mg/kg cap, implemented in December 2025 to balance efficacy with improved tolerability.
3. Combination Trial Progress and Preclinical Synergy
The ongoing Phase 1/2 study combining MICVO with pembrolizumab in 1L R/M HNSCC is in dose escalation with data due in the second half of 2026, bolstered by preclinical findings demonstrating synergistic tumor control when MICVO is paired with PD-1 blockade.
4. Corporate Leadership Appointment
Nelson Azoulay has been named Chief Business Officer, leveraging his prior strategy and business development roles at Flagship Pioneering and ImmunoGen to advance Pyxis’s clinical and partnership initiatives.
